Print Page | Close Page

 

 

Synairgen

Address: Mailpoint 810 Southampton General Hospital, Tremona Road, Southampton, SO16 6YD
 
Country: United Kingdom
 
Sectors: Proprietary Research & Manufacture
 
Telephone: +44 (0) 23 8051 2800
 
Fax: +44 (0)23 8051 2800
 
Website: https://www.synairgen.com/
 
- - -
 

About Us

The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.

 

Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Synairgen is currently running a two-part Phase II trial evaluating SNG001, the Company’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate. The Phase II trial, called SG015, has been designed to assess the safety of SNG001 in COPD patients and its clinical benefit in these patients when they have a cold or flu infection, a major driver of COPD exacerbations.

Core to Synairgen’s business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a £5 million upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.

 
- - -
 

Sectors

  • Proprietary Research & Manufacture
 
 
- - -
 

Categories

  • Finished Dosage
  • Clinical Development
 
  • Inhalation Products
  • Interferon
 
- - -
 

Partnership Details

Core to Synairgen’s business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a £5 million upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.

 

Partnership Activites

  • Licensing Out
  • Research and Development
 

Partnership Category Areas

  • Proprietary Formulations-Clinical Development
  • BioPharmaceuticals-Proprietary Formulations
  • Medical Devices
 

Partnership Therapy Areas

  • Respiratory System
  • Products for Obstructive Airway Diseases
 
- - -
 

News

 
26th July 2020
 

Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients

 

Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients − Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo − Patients who received SNG001 were more than twice as likely to recover from COVID-19 as those on placebo − A briefing for journalists will be held via webinar at 12:30 BST today Southampton, UK – 20 July 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. Richard Marsden, CEO of Synairgen, said: "We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised COVID-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’. It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2. In addition, SNG001 has significantly reduced breathlessness, one of the main symptoms of severe COVID-19. This assessment of SNG001 in COVID-19 patients could signal a major breakthrough in the treatment of hospitalised COVID-19 patients. Our efforts are now focused on working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible." The double-blind placebo-controlled trial recruited 101 patients from 9 specialist hospital sites in the UK during the period 30 March to 27 May 2020. Patient groups were evenly matched in terms of average age (56.5 years for placebo and 57.8 years for SNG001), comorbidities and average duration of COVID-19 symptoms prior to enrolment (9.8 days for placebo and 9.6 days for SNG001). 

 
- - -
 
Printed: 26-Jan-2021 at 17:53:18 hrs
Source: Surims Ltd | https://www.pharmaservicesdirectory.com